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Abstract
The availability of rare monosaccharides that cannot be isolated from natural sources is currently limiting the access to the syn-
thesis and the biological evaluation of complex bacterial cell-surface glycans. Here, we report the synthesis of D- and L-fucosamine
building blocks by a de novo approach from L- and D-Garner aldehydes. These differentially protected monosaccharide building
blocks were utilized to prepare disaccharides present on the surface of Pseudomonas aeruginosa bacteria.
Introduction
Protein functions are directly influenced by their glycosylation
patterns [1,2]. Therefore, an understanding of protein glycosy-
lation is of utmost importance in order to develop new therapeu-
tics [3-6]. The ability of bacteria to colonize human hosts and
cause diseases is directly influenced by their capacity to synthe-
size glycoproteins and express them on cell surfaces. This evi-
dence makes it particularly relevant especially for the identifica-
tion of novel antibacterial agents as well as vaccines [7-9].
Those bacterial glycans often contain unusual monosaccharides
that are not present in the human body. An immune response
against these cell-surface glycans is the basis for the develop-
ment of new vaccine candidates against bacterial infections [10-
13].
Our efforts were directed to the development of new vaccine
candidates [14-16] to prevent bacterial infections, including
glycans of the highly pathogenic bacteria Pseudomonas aerugi-
nosa. P. aeruginosa is a nosocomial pathogen that is involved
in ventilator-associated pneumonia and has become resistant to
many antimicrobials. The somatic pili of P. aeruginosa are a
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Scheme 1: Retrosynthetic analysis of D- and L-fucosamine building blocks.
major virulence factor playing a pivotal role in the adherence
and invasiveness of the bacterium. In 2001, the P. aeruginosa
pilin O-linked glycans were found to be linear trisaccharides
that are covalently attached to serine (Figure 1). The O-glycans
contain a D-fucosamine residue at the protein-binding site. This
unusual monosaccharide is not present in eukaryotes, and there-
fore may be used to stimulate an antibacterial response in the
host organism [17-23]. Access to differentially protected D- and
L-fucosamine building blocks, which can be used in preparing
the corresponding glycans, is instrumental for the evaluation of
oligosaccharide-based vaccine candidates against this bacterium
[24-28].
The synthesis of fucosamine building blocks has been reported
in the literature, but it is highly affected by long synthetic
sequences, extensive protecting group manipulations and
expensive starting materials [29-33]. The de novo synthesis of
rare sugars [34-43] provides an attractive alternative for rapid
access to the required building blocks, but this approach has not
been reported for D- or L-fucosamine [29-33,44-46].
Here, a full account of the de novo synthesis of differentially
protected D- and L-fucosamine building blocks is described
following a recent preliminary communication [47]. The
building blocks prepared by de novo synthesis were used in the
assembly of two disaccharides that are found on P. aeruginosa.
Results and Discussion
De novo synthesis of D- and L-fucosamine
building blocks
Our retrosynthetic analysis of D-fucosamine envisioned the
installation of the syn-1,2-diol unit by osmium-catalysed dihy-
droxylation of allylic ether A. It was anticipated that the con-
formation adopted by the molecule would allow for the forma-
tion of the required anti relationship between C3 and C4
hydroxy groups. A in turn would be accessed by the addition of
Figure 1: Structure of some O-linked glycans found on the cell surface
of P. aeruginosa.
a carbon nucleophile to L-Garner aldehyde L-1 (Scheme 1)
[48]. The fact that D- and L-Garner aldehydes are commer-
cially available greatly facilitates the synthesis of both D- and
L-fucosamine building blocks. The fucosamine residues are
usually further elongated at the C3 position in P. aeruginosa
requiring two orthogonal protecting groups (PGs) at C3 and C4
Beilstein J. Org. Chem. 2013, 9, 332–341.
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Scheme 2: (A) Synthesis of aldehydes 6a and 6b. (B) Alkyne reduction by hydrosilylation–protodesilylation sequence (see Table 1).
of the building block in order to differentiate the two hydroxy
groups at a later stage.
The three carbon C4–C6 fragment of D-fucosamine was intro-
duced by chelation-controlled addition [49,50] of commercially
available propynylmagnesium bromide to L-1 (Scheme 2A)
[51,52] The following E-selective alkyne reduction was accom-
plished by using diluted RedAl in Et2O [53]. This reaction
proved to be highly dependent on the quality of the aluminium
reagent obtained from commercial sources. Inspired by the
work from the Trost group [54,55], an alternative reduction
protocol based on a Ru-catalyzed hydrosilylation–protodesilyla-
tion sequence was pursued (Scheme 2B). Thus, exposure of
alkyne 2 to Cp*Ru(CH3CN)3PF6 catalyst in the presence of the
appropriate trialkylsilane gave the desired silylated products
7a–c (Table 1). The alkene geometry was confirmed as Z by
nuclear Overauser effect (nOe). Treatment of 7a–c with TBAF
and CuI delivered 3 in high yields. Generally, BnMe2SiH has
been found to be optimal for these transformations [54,55]. In
our hands however, the best results were achieved using the
cheaper Et3SiH (Table 1). With a gram amount of 3 in hand, the
C3 hydroxy group was protected and the acetonide removed by
treatment with p-TSA. Oxidation of primary aminoalcohols
5a–b with the Dess–Martin reagent [56] yielded the desired
aldehydes 6a–b, in five steps from commercially available
starting materials. The two different O-protecting groups,
namely naphthyl ether (Nap) [57-59] and benzoate ester (Bz),
were introduced to gain access to two sets of electronically
different and orthogonally protected derivatives (Scheme 2A).
Table 1: Hydrosilylation yields.
entry R yield (%)
1 7a: Et3 81
2 7b: Et2Me 71
3 7c: Me2Bn traces
Dihydroxylation of aldehyde 6a under standard Upjohn condi-
tions gave, after peracetylation with Ac2O, D-fucosamine
building block D-8a in 81% yield and 5:1 dr (anti/syn, dia-
stereomers separable by column chromatography) (Scheme 3)
[60-62]. The formation of the desired C3–C4–C5 syn,syn cyclic
product was confirmed based on observation of a 3JH3–H4
coupling of 3.5 Hz. When the same sequence of dihydroxy-
lation–peracetylation was performed on Bz-substituted alde-
hyde 6b, compound D-8b was formed in 71% as a single
diastereomer (Scheme 3). This product was crystallized from
n-hexane/EtOAc solvent mixture, and the stereochemical
assignment was confirmed by X-ray analysis (data shown in
Supporting Information File 1).
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Scheme 3: Synthesis of D-fucosamine building blocks 8a and 8b.
Scheme 4: Epimerization of aldehyde 6a.
Table 2: Oxidation of 5a to D-fucosamine D-8a.
entry reaction conditions D-Fuc/D-Tala
1b DMP, CH2Cl2, rt then 1 M Na2S2O3 in NaHCO3, sat. >20:1
2 DMSO, (COCl)2, Et3N, CH2Cl2, −78 °C 2:1
3 DMSO, (COCl)2, iPr2NEt, CH2Cl2, −78 °C 8:1
4 SO3·pyr, DMSO, CH2Cl2, 0 °C 2:1
5 TCCA, TEMPO, CH2Cl2, 0 °C 3:1
aDetermined by 1H NMR analysis of the crude product after dihydroxylation and peracetylation. bReaction run on 1 g scale.
During the optimization of the synthetic sequence we explored
potentially more economic oxidation protocols to convert the
primary alcohol 5a to the D-fucosamine building block. Since
α-amino protected aldehydes easily undergo α-epimerization,
oxidation had to proceed under mild conditions in order to
avoid the formation of the undesired D-talosamine building
block D-9 (Scheme 4).
Several oxidation methods were tested (Table 2). All the reac-
tions were performed sequentially without column-chromato-
graphic purification of the aldehyde. Classic Swern oxidation
[63] (Table 2, entry 2) gave a 2:1 mixture of C2 epimers
demonstrating the acid lability of aldehyde 6a. This ratio in
favour of the desired product was improved to 8:1 by switching
the base from Et3N to iPr2EtN as reported by Dondoni and
co-workers (Table 2, entry 3) [64]. Parrikh–Doering oxidation
[65] and TCCA–TEMPO mediated oxidation [66] (Table 2,
entries 4 and 6, respectively) were not suitable as considerable
amounts of D-talosamine building block were formed. DMP
emerged as the reagent of choice for the oxidation of 5a. Inter-
estingly, the dihydroxylation of aldehyde epi-6a resulted in the
formation of talosamine D-9 as a single diastereomer while the
dihydroxylation of 6a gave D-8a in 5:1 dr (Scheme 3).
Carrying out the synthetic sequence optimized for the synthesis
of D-8a, on D-Garner aldehyde (D-1, commercially available)
Beilstein J. Org. Chem. 2013, 9, 332–341.
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Scheme 5: Synthesis of L-fucosamine building block L-8a from D-Garner aldehyde.
gave alcohol ent-5a (four steps, two chromatographic purifica-
tions) that after the direct oxidation–dihydroxylation–peracety-




To facilitate the use of the bacterial monosaccharides in the
glycan microarray platform and their conjugation to carrier
proteins, an appropriate linker was required at the anomeric
position [67]. Placement of a C3 naphthyl ether anticipated the
site for further glycosylation at this position, which typically
serves as the connection to the next sugar. Therefore, building
block 8a is ideal in terms of orthogonality and chemical syn-
thesis. Hence, we tested the ability of D-8a to undergo anomeric
functionalization and to effect glycosylation at the C3 hydroxy
group. Due to the presence of N-acetylated D- and
L-fucosamine residues in P. aeruginosa O-linked glycans, the
strategic N-protecting group was evaluated. Direct glycosy-
lation by using the building block D-8a was not possible.
Hence, a direct N-Boc deprotection/N-acetylation sequence
afforded D-10 in 84% yield (Scheme 6A). Direct glycosylation
of D-10 by using glycosylating agent 11 [67] and BF3·Et2O as
the activating agent, yielded the linker-functionalized monosac-
charide D-12 as the β-anomer (3JH1–H2 = 8.3 Hz, Scheme 6A).
At this point, the C3 naphthyl ether was cleaved under oxida-
tive conditions and the corresponding alcohol was revealed by
using a two-step deprotection protocol consisting of ester
hydrolysis and hydrogenation. Monosaccharide D-13 was
obtained in 85% yield (the β-linkage further confirmed by
1JC1–H1 164.1 Hz, Scheme 6A). Direct glycosylation after
DDQ-deprotection was possible and the use of differentially
protected glucose building block 15 [68] yielded the desired
β-disaccharide 16 in 61% yield over two steps (β anomer,
3JH1–H2 of 7.8 Hz, Scheme 6A). Global deprotection employed
saponification, and hydrogenation gave the fully deprotected
D-fucosamine containing disaccharide 17 (Scheme 6A).
When the same synthetic sequence was performed on
L-FucNAc building block L-10 the fully deprotected monomer
L-13 and disaccharide 19 were obtained in similar yields and
selectivities (Scheme 6B). Diagnostic 1JC–H analysis also
corroborated the formation of the β-glycosydic linkages
(Scheme 6B). Linker-terminated disaccharide 19 represents the
terminal unit of the P. aeruginosa serotype O11 O-linked
glycan (Figure 1).
Conclusion
The de novo synthesis of differentially protected D- and
L-fucosamine building blocks from D- and L-Garner aldehyde
is reported. Placement of a naphthyl ether protecting group at
the C3 position allows for further elongation by glycosylation.
The key oxidation step was optimized to minimize the forma-
tion of the unwanted D-talosamine building block D-9. The
fucosamine building blocks prepared by de novo synthesis
enabled the preparation of monosaccharides and disaccharides
for attachment to microarray surfaces. The terminal disaccha-
ride of P. aeruginosa O11 O-linked glycan has been prepared




All reagents were obtained from commercial suppliers and were
used without further purification unless otherwise specified. All
reactions were conducted under an Ar atmosphere by using
standard Schlenk techniques. THF and Et2O were distilled from
purple Na/benzophenone diketyl; CH2Cl2, pyridine and
BF3·Et2O were distilled from CaH2. Deionized water was
obtained from an in-house purification system. The compounds
purified by flash chromatography were further concentrated by
the removal of residual solvent under high vacuum (<0.2 mbar).
1H NMR and 13C NMR spectra were measured with a Varian
400-MR or Varian 600 spectrometer. The proton signal of
residual, nondeuterated solvent (δ 7.26 ppm for CHCl3 or δ 4.79
ppm for HDO) was used as an internal reference for 1H spectra.
For 13C spectra, the chemical shifts are reported relative to the δ
77.36 ppm resonance of CDCl3. Coupling constants (J values)
are quoted to one decimal place with values in hertz (Hz) and
were corrected. Infrared (IR) spectra were recorded as thin films
on a Perkin Elmer Spectrum 100 FTIR spectrophotometer.
Optical rotations (OR) were measured with a Schmidt &
Haensch UniPol L 1000 spectrometer at a concentration (c)
expressed in grams per hundred millilitres (g/100 mL). High-
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Scheme 6: Synthesis of D- and L-fucosamine-containing mono- and disaccharides carrying the pentanolamine linker.
Beilstein J. Org. Chem. 2013, 9, 332–341.
338
resolution mass spectra (HRMS) were recorded with an Agilent
6210 ESI–TOF mass spectrometer at the Freie Universität
Berlin, Mass Spectrometry Core Facility. Analytical thin-layer
chromatography (TLC) was performed on Kieselgel 60 F254
glass plates precoated with a 0.25 mm thickness of silica gel.
The TLC plates were visualized with UV light and by staining
with Hanessian solution (ceric sulfate and ammonium molyb-
date in aqueous sulfuric acid) or potassium permanganate solu-
tion (potassium permanganate in basic aqueous solution).
Column chromatography was performed by using Kieselgel 60
(230–400 mesh) silica gel with a typical 50–100:1 weight ratio
of silica gel to crude product. For the preparation and character-
ization of compounds 2–10, D-12 and D-16 see [14].
L-Fucosamine monosaccharide L-12
Under the same reaction conditions reported in [14], L-10
(75 mg, 0.17 mmol, 1.0 equiv), 11 (86 mg, 0.26 mmol,
1.5 equiv) and BF3·Et2O (33 mL, 0.26 mmol, 1.5 equiv) gave
L-12 (74 mg, 61%) as an oil; [α]D20 −63.2 (c 2.0, CHCl3), other
data as above.
D-Fucosamine monosaccharide D-13
A solution of D-12 (56 mg, 80.0 mmol, 1.0 equiv) in CH2Cl2
(0.9 mL) and H2O (90 mL) was treated with DDQ (21 mg,
94.0 mmol, 1.2 equiv) and stirred in the dark at rt for 2 h. Satu-
rated NaHCO3 (2 mL) and CH2Cl2 (5 mL) were added and the
layers were separated. The aqueous layer was extracted with
CH2Cl2 (2 × 3 mL). The combined organic layers were dried
(MgSO4), filtered and concentrated. The crude was purified by
filtration over a short plug of silica gel eluting with CH2Cl2/
MeOH 9:1 (34 mg, 76%) and immediately used for the next
step. The monodeprotected compound (18 mg, 32.0 mmol,
1.0 equiv) in MeOH (0.4 mL) and THF (0.4 mL) was treated
with KOH (1.8 mg, 32.0 mmol, 1.0 equiv) and stirred at rt for
30 min. H2O (2 mL) was added and the solvents were removed
under vacuum. CH2Cl2 (5 mL) was added and the layers were
separated. The aqueous layer was extracted with CH2Cl2
(2 × 5 mL). The combined organic layers were dried (MgSO4),
filtered and concentrated. The crude product was solubilised in
MeOH/H2O/AcOH (2.0:1.0:0.05 mL) and Pd/C (10 mg) was
added. The heterogeneous mixture was stirred under an atmos-
phere of H2 for 24 h. The mixture was filtered over celite to
give D-13 (8 mg, 85%) as an amorphous solid; [α]D20 +112.9 (c
1.1, H2O); 1H NMR (400 MHz, D2O) δ 4.38 (d, J = 8.4 Hz, 1H,
CHF), 3.83 (dt, J = 10.1, 6.3 Hz, 1H, CHG), 3.79 (dd, J = 10.7,
8.4 Hz, 1H, CHE), 3.75–3.69 (m, 2H, CHC and NH), 3.68 (dd, J
= 10.7, 3.4 Hz, 1H, CHD), 3.66 (dt, J = 10.1, 6.3 Hz, 1H, CHG),
3.41 (q, J = 6.4 Hz, 1H, CHB), 2.95 (t, J = 7.6 Hz, 2H, CH2K),
1.99 (s, 3H, CH3), 1.87 (AcOH), 1.71–1.62 (m, 2H, CH2J),
1.59–1.51 (m, 2H, CH2H), 1.39–1.29 (m, 2H, CH2I), 1.23 (d, J
= 6.4 Hz, 3H, CH3A); 13C NMR (100 MHz, D2O) δ 101.4
(CHF), 71.0 (CHD), 70.4 (CHC), 70.3 (CHB), 69.8 (CH2G), 52.0
(CHE), 39.2 (CH2K), 28.0 (CH2J), 26.3 (CH2H), 23.1 (CH3),
22.1 (CH3), 21.9 (CH2I), 15.3 (CH3A); LRMS–ESI (m/z): 291.2
[M + H+]; HRMS–ESI (m/z): [M + H+] calcd for C13H27N2O5,
291.1914; found, 291.1919.
L-Fucosamine monosaccharide L-13
Using the same reaction conditions reported for D-13, D-12
(24 mg, 34.0 mmol, 1.0 equiv), DDQ (21 mg, 41.0 mmol,
1.2 equiv), KOH (1.8 mg, 34.0 mmol, 1.0 equiv) and Pd/C
(10 mg), gave L-13 (9 mg, 75%) as an amorphous solid; [α]D20
−111.1 (c 1.0, H2O), other data as above.
D-Fucosamine disaccharide 17
A solution of 16 (21 mg, 19.0 mmol, 1.0 equiv) in MeOH
(0.4 mL) and THF (0.4 mL) was treated with KOH (1.0 mg,
19.0 mmol, 1.0 equiv) and stirred at rt for 30 min. H2O (2 mL)
was added and the solvents were removed under vacuum.
CH2Cl2 (5 mL) was added and the layers were separated. The
aqueous layer was extracted with CH2Cl2 (2 × 5 mL). The
combined organic layers were dried (MgSO4), filtered and
concentrated. The crude product was solubilised in MeOH/H2O/
AcOH (2.0:1.0:0.05 mL) and Pd/C (20 mg) was added. The
heterogeneous mixture was stirred under an atmosphere of H2
for 24 h. The mixture was filtered over celite to give 17 (9 mg,
91%) as an amorphous solid; [α]D20 +13.5 (c 0.9, H2O);
1H NMR (400 MHz, D2O) δ 4.47 (d, J = 7.9 Hz, 1H, CHG),
4.41 (d, J = 7.9 Hz, 1H, CHF), 3.94 (d, J = 2.7 Hz, 1H, CHC),
3.90 (dd, J = 10.3, 7.9 Hz, 1H, CHE), 3.87–3.77 (m, 3H, CHL &
CHM & CHD), 3.70 (q, J = 6.5 Hz, 1H, CHB), 3.68 (dd, J =
12.1, 3.4 Hz, 1H, CHL), 3.54 (dt, J = 10.0, 6.2 Hz, 1H, CHM),
3.44–3.32 (m, 3H, CHI, CHJ and CHK), 3.25 (t, J = 7.9 Hz, 1H,
CHH), 2.94 (t, J = 7.6 Hz, 2H, CH2Q), 1.97 (s, 3H, CH3), 1.90
(s, 3H, AcOH), 1.68–1.59 (m, 2H, CH2P), 1.58–1.50 (m, 2H,
CH2N), 1.41–1.32 (m, 2H, CH2O), 1.22 (d, J = 6.5 Hz, 3H,
CH3A); 13C NMR (100 MHz, D2O) δ 104.2 (CHG), 101.1
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(CHF), 80.2 (CHD), 75.5 (CH), 75.4 (CH), 72.7 (CHH), 70.4 (2
× CHB&C), 69.8 (CH2L), 69.2 (CH), 60.3 (CH2M), 50.8 (CHE),
39.1 (CH2Q), 28.0 (CH2N), 26.2 (CH2P), 23.1 (CH3), 22.1
(CH3), 22.0 (CH2O), 15.3 (CH3A); LRMS–ESI (m/z): 453.2 [M
+ Na+]; HRMS–ESI (m/z): [M + H+] calcd for C19H37N2O10,
453.2443; found, 453.2468.
L-Fucosamine disaccharide 18
A solution of L-12 (60 mg, 86 mmol, 1.0 equiv) in CH2Cl2
(1 mL) and H2O (0.1 mL) was treated with DDQ (21 mg,
95 mmol, 1.2 equiv) and stirred in the dark at rt for 2 h. Satu-
rated NaHCO3 (2 mL) and CH2Cl2 (5 mL) were added and the
layers were separated. The aqueous layer was extracted with
CH2Cl2 (2 × 3 mL). The combined organic layers were dried
(MgSO4), filtered and concentrated. The crude was purified by
filtration over a short plug of silica gel eluting with CH2Cl2/
MeOH (9:1) and immediately used for the next step. An oven-
dried flask was immediately charged with the product and 15
(77 mg, 0.12 mmol, 1.5 equiv) was added. The flask was left
under high vacuum for 4 h. After refilling the flask with argon,
freshly distilled CH2Cl2 (1.5 mL) was added, and the mixture
was cooled to −30 °C. NIS (29 mg, 0.13 mmol, 1.5 equiv) and
TfOH (4 mL, 43 mmol, 0.5 equiv) were added. The mixture
was stirred at −30 °C for 4 h and then it was allowed to warm to
rt overnight. Saturated Na2SO3 (3 mL) and CH2Cl2 (3 mL)
were added and the layers were separated. The aqueous layer
was extracted with CH2Cl2 (2 × 5 mL). The combined organic
layers were dried (MgSO4), filtered and evaporated. Purifica-
tion by column chromatography on silica gel, eluting with
n-hexane/EtOAc (6:4), gave 18 (45 mg, 48%) as an oil; Rf 0.22
[n-hexane/EtOAc (4:1)]; [α]D20 −5.5 (c 0.3, CHCl3); FTIR
(film) νmax (cm−1): 3321, 2925, 2857, 1743, 1716, 1705, 1662,
1368, 1271, 1240, 1071; 1H NMR (400 MHz, CDCl3, rotamers)
δ 8.04 (d, 2H, J = 7.3 Hz, 2 × CH), 7.57 (tt, J = 7.4, 1H, 1.2
CH), 7.44 (t, J = 7.7 Hz, 2H, 2 × CH), 7.35–7.22 (m, 17H, 17 ×
CH), 7.17–7.04 (m, 8H, 8 × CH), 5.88 (br d, J = 6.5 Hz, 0.5H,
NH), 5.73 (br d, J = 6.0 Hz, 0.5H, NH), 5.21 (dd, J = 9.1,
8.0 Hz, 1H, CHH), 5.17 (br s, 1H, CHQ), 5.14 (br s, 1H, CHQ),
5.13 (d, J = 3.5 Hz, 1H, CHC), 5.07 (d, J = 8.0 Hz, 1H, CHF),
4.79 (d, J = 10.8 Hz, 1H, CHM), 4.70 (d, J = 11.0 Hz, 1H,
CHM), 4.65–4.53 (m, 6H, CHD & CHG & 4 × CHM), 4.52–4.46
(m, 2H, CH2R), 3.86 (t, J = 9.3 Hz, 1H, CHI), 3.82–3.74 (m,
4H, CHJ, CH2L, CHN), 3.67 (q, J = 6.4 Hz, 1H, CHB), 3.50 (br
dt, J = 9.6, 2.3 Hz, 1H, CHK), 3.44–3.40 (m, 1H, CHN),
3.23–3.17 (m, 3H, CHE and CH2P), 1.85 and 1.81 (s, 3H, CH3),
1.53–1.50 (m, 3H, 3 × CHO), 1.45 (s, 3H, CH3), 1.29–1.21 (m,
3H, 3 × CHO), 1.08 (d, J = 6.4 Hz, 3H, CH3A); 13C NMR
(100 MHz, CDCl3, rotamers) δ 171.2 (C=O), 170.5 (C=O),
165.1 (C=O), 137.9 (2 × C), 137.7 (2 × C), 137.6 (C), 133.2 (2
× CH), 130.1 (2 × CH), 129.5 (C), 128.5 (2 × CH), 128.4 (4 ×
CH), 128.3 (4 × CH), 128.2 (4 × CH), 127.9 (2 × CH), 127.8 (4
× CH), 127.7 (CH), 127.6 (CH), 127.3 (CH), 127.2 (CH), 127.1
(CH), 99.6 (CH), 98.4 (CH), 82.9 (CH), 77.7 (CH), 75.2 (CH2),
75.0 (CH2), 74.7 (CH), 73.5 (CH), 73.4 (CH2), 72.5 (CH), 69.7
and 69.5 (CH2), 69.1 (CH), 68.9 (CH), 68.7 (CH2), 67.1 (CH2),
54.4 (CH), 50.4 and 50.1 (CH2), 47.1 and 46.1 (CH2), 29.7 and
29.1 (CH2), 27.8 and 27.4 (CH2), 23.5 (CH3), 23.1 (CH2), 19.9
(CH3), 16.4 (CH3); LRMS–ESI (m/z): 1115.4 [M + Na+].
L-Fucosamine disaccharide 19
A solution of 18 (29 mg, 27.0 mmol, 1.0 equiv) in MeOH
(0.6 mL) and THF (0.6 mL) was treated with KOH (0.8 mg,
13.5 mmol, 0.5 equiv) and stirred at rt for 30 min. H2O (2 mL)
was added and the solvents were removed under vacuum.
CH2Cl2 (5 mL) was added and the layers were separated. The
aqueous layer was extracted with CH2Cl2 (2 × 5 mL). The
combined organic layers were dried (MgSO4), filtered and
concentrated. The crude product was solubilised in MeOH/H2O/
AcOH (3.0:1.5:0.06 mL) and Pd/C (30 mg) was added. The
heterogeneous mixture was stirred under an atmosphere of H2
for 24 h. The mixture was filtered over celite to give 19 (10 mg,
74%) as an amorphous solid; [α]D20 +59.2 (c 0.9, H2O);
1H NMR (400 MHz, D2O) δ 4.48 (d, J = 7.9 Hz, 1H, CHG),
4.43 (d, J = 7.9 Hz, 1H, CHF), 3.96–3.89 (m, 3H, CHC, CHD
and CHL), 3.88–3.80 (m, 2H, CHE and CHM), 3.72 (q, J =
6.5 Hz, 1H, CHB), 3.67 (dd, J = 12.1, 6.5 Hz, 1H, CHL), 3.56
(dt, J = 10.2, 6.2 Hz, 1H, CHM), 3.45 (t, J = 9.5 Hz, 1H, CHI),
3.42–3.46 (m, 1H, CHJ), 3.36–3.31 (m, 1H, CHK), 3.27 (dd, J =
9.5, 7.9 Hz, 1H, CHH), 2.95 (t, J = 7.6 Hz, 2H, CH2Q), 1.99 (s,
3H, CH3), 1.97 (s, 3H, AcOH), 1.69–1.60 (m, 2H, CH2P),
1.59–1.50 (m, 2H, CH2N), 1.42–1.32 (m, 2H, CH2O), 1.26 (d, J
= 6.5 Hz, 3H, CH3A); 13C NMR (100 MHz, D2O) δ 177.0
(C=O), 103.9 (CHF), 102.7 (CHG), 80.1 (CHD), 79.5 (CHI),
Beilstein J. Org. Chem. 2013, 9, 332–341.
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77.9 (CHJ), 75.3 (CHB), 73.0 (CHH), 72.4 (CH2L), 72.2 (CHK),
70.4 (CHC), 63.5 (CH2M), 52.8 (CHE), 41.7 (CH2Q), 30.5
(CH2N), 28.8 (CH2P), 24.8 (CH3), 24.5 (CH2O), 24.4 (CH3),
17.8 (CH3); LRMS–ESI (m/z): 453.2 [M + H+]; HRMS–ESI (m/
z): [M + H+] calcd for C19H37N2O10, 453.244; found,
453.2468.
Supporting Information
Supporting Information File 1
1H NMR, COSY, 13C NMR and HSQC spectra and the
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